NCT00672919View on ClinicalTrials.gov

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

PHASE4CompletedINTERVENTIONAL

Enrollment

305

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

August 31, 2004

Study Completion Date

August 31, 2004

Conditions

Diabetes Mellitus

Interventions

DRUG

Pioglitazone

Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.

Trial Locations (53)

Unknown

Birmingham

Tucson

Bellflower

Burlingame

Fresno

La Jolla

Long Beach

Pasadena

Arvada

Norwalk

Waterbury

Aventura

Hollywood

Jacksonville

Miami

North Miami Beach

Tallahassee

West Palm Beach

Columbus

Idaho Falls

Chicago Heights

Evansville

Des Moines

Lafayette

Fall River

Waltham

Tupelo

Chesterfield

Omaha

Staten Island

Raleigh

Winston-Salem

Centerville

Dayton

Medford

Meadville

Pittsburgh

Warwick

Chattanooga

Morristown

Murfreesboro

Nashville

Arlington

Houston

Midland

San Antonio

Ogden

Orange

Virginia Beach

Man

Wausau

Carolina

Ponce

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY

NCT00672919 - Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone. | Biotech Hunter | Biotech Hunter